RS55315B2 - Miš sa zajedničkim lakim lancem - Google Patents
Miš sa zajedničkim lakim lancemInfo
- Publication number
- RS55315B2 RS55315B2 RS20161014A RSP20161014A RS55315B2 RS 55315 B2 RS55315 B2 RS 55315B2 RS 20161014 A RS20161014 A RS 20161014A RS P20161014 A RSP20161014 A RS P20161014A RS 55315 B2 RS55315 B2 RS 55315B2
- Authority
- RS
- Serbia
- Prior art keywords
- light chain
- common light
- chain mouse
- mouse
- common
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knockout animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Humanized animals, e.g. knockin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30228210P | 2010-02-08 | 2010-02-08 | |
EP12173456.0A EP2505654B2 (en) | 2010-02-08 | 2011-02-08 | Common light chain mouse |
Publications (2)
Publication Number | Publication Date |
---|---|
RS55315B1 RS55315B1 (sr) | 2017-03-31 |
RS55315B2 true RS55315B2 (sr) | 2020-08-31 |
Family
ID=43663643
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20190849A RS59001B1 (sr) | 2010-02-08 | 2011-02-08 | Miš sa zajedničkim lakim lancem |
RS20150772A RS54367B2 (sr) | 2010-02-08 | 2011-02-08 | Miš sa zajedničkim lakim lancem |
RS20161014A RS55315B2 (sr) | 2010-02-08 | 2011-02-08 | Miš sa zajedničkim lakim lancem |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20190849A RS59001B1 (sr) | 2010-02-08 | 2011-02-08 | Miš sa zajedničkim lakim lancem |
RS20150772A RS54367B2 (sr) | 2010-02-08 | 2011-02-08 | Miš sa zajedničkim lakim lancem |
Country Status (30)
Country | Link |
---|---|
US (5) | US10143186B2 (sr) |
EP (4) | EP2501817B2 (sr) |
JP (8) | JP5955781B2 (sr) |
KR (5) | KR102283195B1 (sr) |
CN (2) | CN105010238B (sr) |
AU (1) | AU2011213585B2 (sr) |
BR (2) | BR122014002928A2 (sr) |
CA (1) | CA2789154A1 (sr) |
CY (2) | CY1118241T1 (sr) |
DK (3) | DK2505654T4 (sr) |
ES (3) | ES2603559T5 (sr) |
HK (2) | HK1231505A1 (sr) |
HR (3) | HRP20151188T4 (sr) |
HU (3) | HUE029785T2 (sr) |
IL (3) | IL221265B (sr) |
LT (2) | LT3095871T (sr) |
ME (2) | ME02288B (sr) |
MX (3) | MX2012009168A (sr) |
MY (1) | MY166529A (sr) |
NZ (4) | NZ601679A (sr) |
PL (3) | PL2501817T5 (sr) |
PT (3) | PT2501817E (sr) |
RS (3) | RS59001B1 (sr) |
RU (2) | RU2724663C2 (sr) |
SG (4) | SG10201913463QA (sr) |
SI (3) | SI3095871T1 (sr) |
SM (2) | SMT201500283B (sr) |
TR (1) | TR201906650T4 (sr) |
WO (1) | WO2011097603A1 (sr) |
ZA (1) | ZA201205944B (sr) |
Families Citing this family (187)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
ATE514717T1 (de) | 2002-07-18 | 2011-07-15 | Merus B V | Rekombinante produktion von antikörpermischungen |
US20100069614A1 (en) * | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
EP2395016A3 (en) | 2003-05-30 | 2012-12-19 | Merus B.V. | Design and use of paired variable regions of specific binding molecules |
EP2064325B1 (en) | 2006-09-01 | 2011-12-07 | Therapeutic Human Polyclonals, Inc. | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
RU2559524C2 (ru) * | 2008-06-27 | 2015-08-10 | Мерюс Б.В. | Продуцирующие антитела млекопитающие, не являющиеся человеком |
JP5827127B2 (ja) | 2008-12-18 | 2015-12-02 | エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム | ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用 |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
PT2517556E (pt) * | 2009-07-08 | 2016-01-20 | Kymab Ltd | Modelos animais e moléculas terapêuticas |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
US20120021409A1 (en) * | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
LT3095871T (lt) * | 2010-02-08 | 2019-05-27 | Regeneron Pharmaceuticals, Inc. | Bendros lengvosios grandinės pelė |
BR112012033248A2 (pt) * | 2010-06-22 | 2017-11-28 | Regeneron Pharma | camundongos expressando uma cadeia leve com variável de lâmbda humana e regiões constantes de camundongo |
SG10201912639SA (en) | 2010-08-02 | 2020-02-27 | Regeneron Pharma | Mice that make binding proteins comprising vl domains |
CN103348012B (zh) * | 2010-11-27 | 2016-06-08 | 朱坚 | 一种人源化的转基因动物 |
SG10201913160QA (en) | 2011-02-25 | 2020-03-30 | Regeneron Pharma | Adam6 mice |
WO2012116926A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Antigen binding proteins |
KR101572338B1 (ko) | 2011-02-28 | 2015-11-26 | 에프. 호프만-라 로슈 아게 | 1가 항원 결합 단백질 |
US10130081B2 (en) * | 2011-08-05 | 2018-11-20 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
WO2013041845A2 (en) * | 2011-09-19 | 2013-03-28 | Kymab Limited | Animals, repertoires & methods |
BR112014006394A2 (pt) | 2011-09-19 | 2017-03-28 | Kymab Ltd | manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos |
GB2495083A (en) * | 2011-09-26 | 2013-04-03 | Kymab Ltd | Human VpreB and chimaeric surrogate light chains in transgenic non-human vertebrates |
CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
ES2757473T3 (es) * | 2011-09-30 | 2020-04-29 | Dana Farber Cancer Inst Inc | Péptidos terapéuticos que comprenden anticuerpos que se unen a la secuencia A relacionada con el polipéptido del CMH de clase I (MICA) |
IN2014CN03572A (sr) | 2011-10-17 | 2015-10-09 | Regeneron Pharma | |
EP2770823A4 (en) | 2011-10-28 | 2015-12-09 | Trianni Inc | TRANSGENIC ANIMALS AND METHOD FOR THEIR USE |
US9253965B2 (en) * | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
KR101924805B1 (ko) | 2011-12-20 | 2018-12-04 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 경쇄 마우스 |
UY34652A (es) | 2012-03-02 | 2013-09-02 | Regeneron Pharma | Anticuerpos humanos frente a toxinas de clostridium difficile |
EP3165086A1 (en) * | 2012-03-06 | 2017-05-10 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
AU2013204581B2 (en) * | 2012-03-16 | 2015-06-25 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing pH-sensitive immunoglobulin sequences |
RS59076B1 (sr) * | 2012-03-16 | 2019-09-30 | Regeneron Pharma | Glodari koji eksprimiraju imunoglobulinske sekvence senzitivne na ph |
CN104302169B (zh) | 2012-03-16 | 2017-11-17 | 瑞泽恩制药公司 | 组氨酸工程改造的轻链抗体和用于生成所述抗体的经基因修饰的非人动物 |
US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
AU2015227453B2 (en) * | 2012-03-16 | 2017-05-25 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing ph-sensitive immunoglobulin sequences |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
US9248181B2 (en) * | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
KR102089526B1 (ko) | 2012-05-10 | 2020-03-17 | 바이오아트라, 엘엘씨 | 다중-특이적 모노클로날 항체 |
KR20150023535A (ko) * | 2012-06-05 | 2015-03-05 | 리제너론 파마슈티칼스 인코포레이티드 | 공통 경쇄를 사용하여 완전한 인간 이중 특이적 항체를 만드는 방법 |
SG10201913429WA (en) | 2012-06-12 | 2020-03-30 | Regeneron Pharma | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
JO3462B1 (ar) | 2012-08-22 | 2020-07-05 | Regeneron Pharma | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
US10358492B2 (en) * | 2012-09-27 | 2019-07-23 | Merus N.V. | Bispecific IgG antibodies as T cell engagers |
EP2943511B1 (en) | 2013-01-14 | 2019-08-07 | Xencor, Inc. | Novel heterodimeric proteins |
CN105164153B (zh) * | 2013-02-20 | 2020-04-24 | 瑞泽恩制药公司 | 人源化的t细胞共受体的小鼠 |
TR201810255T4 (tr) * | 2013-02-20 | 2018-08-27 | Regeneron Pharma | Modifiye edilmiş immunoglobulin ağır zincir sekanslarına sahip olan insan olmayan hayvanlar. |
PL2958937T3 (pl) * | 2013-02-22 | 2019-01-31 | Regeneron Pharmaceuticals, Inc. | Myszy ekspresjonujące humanizowany główny układ zgodności tkankowej |
EP2967015B9 (en) * | 2013-03-11 | 2023-08-09 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |
SG11201506294TA (en) * | 2013-03-13 | 2015-09-29 | Regeneron Pharma | Common light chain mouse |
FI3501272T3 (fi) * | 2013-03-13 | 2023-04-06 | Regeneron Pharma | Rajallista immunoglobuliinin kevytketjuvalikoimaa ilmentäviä hiiriä |
WO2014141189A1 (en) | 2013-03-14 | 2014-09-18 | Erasmus University Medical Center | Transgenic non-human mammal for antibody production |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
KR102049990B1 (ko) | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
CN105143262A (zh) | 2013-04-29 | 2015-12-09 | 豪夫迈·罗氏有限公司 | 结合人fcrn的修饰的抗体和使用方法 |
US20150033372A1 (en) * | 2013-05-01 | 2015-01-29 | Kymab Limited | Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
CN111019953A (zh) | 2013-09-18 | 2020-04-17 | 瑞泽恩制药公司 | 组氨酸工程改造的轻链抗体和用于生成所述抗体的经基因修饰的非人动物 |
MX2016003617A (es) | 2013-09-30 | 2016-07-21 | Chugai Pharmaceutical Co Ltd | Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado. |
CA2925723A1 (en) * | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
CA2922912A1 (en) | 2013-10-11 | 2015-04-16 | F. Hoffmann-La Roche Ag | Multispecific domain exchanged common variable light chain antibodies |
JP6778110B2 (ja) | 2014-01-15 | 2020-10-28 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 改善されたプロテインA結合を有するFc領域バリアント |
CA2931986A1 (en) | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
WO2015130173A1 (en) | 2014-02-28 | 2015-09-03 | Merus B.V. | Antibody that binds erbb-2 and erbb-3 |
AU2015223566B2 (en) | 2014-02-28 | 2020-10-08 | Merus N.V. | Antibodies that bind EGFR and ErbB3 |
TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
CA3124228A1 (en) * | 2014-03-21 | 2015-09-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
MX2016012273A (es) | 2014-03-21 | 2017-02-23 | Regeneron Pharma | Proteinas de union al antigeno vl que presentan diferentes caracteristicas de union. |
MA44179B1 (fr) | 2014-05-13 | 2020-10-28 | Univ Pennsylvania | Compositions comprenant un virus adeno-associe exprimant des constructions a double anticorps et leurs utilisations |
SG10201810507WA (en) | 2014-06-06 | 2018-12-28 | Bristol Myers Squibb Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
BR112017005245A2 (pt) | 2014-09-19 | 2017-12-12 | Regeneron Pharma | animal não humano geneticamente modificado, métodos para produzir célula t, hibridoma de célula t, um ácido nucleico, um anticorpo específico, uma célula humana, um animal não humano geneticamente modificado e para induzir uma resposta imunológica, célula, hibridoma de célula t, ácido nucleico, anticorpo específico, receptor de antígeno quimérico, embrião não humano, locus de um receptor de antígeno quimérico, e, composição de ácidos nucleicos. |
JP2017531642A (ja) | 2014-10-03 | 2017-10-26 | マサチューセッツ インスティテュート オブ テクノロジー | エボラ糖タンパク質に結合する抗体およびその使用 |
WO2016071377A1 (en) | 2014-11-06 | 2016-05-12 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn- and protein a-binding properties |
RS60739B1 (sr) | 2014-11-17 | 2020-09-30 | Regeneron Pharma | Postupci za lečenje tumora upotrebom cd3xcd20 bispecifičnog antitela |
EP3725808A1 (en) | 2014-11-21 | 2020-10-21 | Bristol-Myers Squibb Company | Antibodies against cd73 and uses thereof |
LT3223845T (lt) | 2014-11-26 | 2021-08-25 | Xencor, Inc. | Heterodimeriniai antikūnai, kurie suriša cd3 ir cd20 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
TWI701258B (zh) | 2014-12-19 | 2020-08-11 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
AU2015365583B2 (en) | 2014-12-19 | 2021-10-28 | Regenesance B.V. | Antibodies that bind human C6 and uses thereof |
BR112017013385A2 (pt) | 2014-12-23 | 2018-02-06 | Bristol-Myers Squibb Company | anticorpos para tigit |
CN107438622A (zh) * | 2015-03-19 | 2017-12-05 | 瑞泽恩制药公司 | 选择结合抗原的轻链可变区的非人动物 |
UY36687A (es) | 2015-05-29 | 2016-11-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Anticuerpos contra ox40 y sus usos |
JP2018526977A (ja) | 2015-06-29 | 2018-09-20 | ザ ロックフェラー ユニヴァーシティ | アゴニスト活性が増強されたcd40に対する抗体 |
EP3722318A1 (en) | 2015-07-06 | 2020-10-14 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
EP3757129A1 (en) | 2015-07-10 | 2020-12-30 | Merus N.V. | Human cd3 binding antibody |
JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
JP7023231B2 (ja) | 2015-09-23 | 2022-02-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 最適化抗cd3二重特異性抗体及びその使用 |
TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗lag3抗體及其用途 |
SG11201803359VA (en) | 2015-10-23 | 2018-05-30 | Merus Nv | Binding molecules that inhibit cancer growth |
US11213586B2 (en) | 2015-11-19 | 2022-01-04 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) |
EP4257599A3 (en) | 2016-01-13 | 2024-01-17 | Regeneron Pharmaceuticals, Inc. | Rodents having an engineered heavy chain diversity region |
EP3423489A1 (en) | 2016-03-04 | 2019-01-09 | The Rockefeller University | Antibodies to cd40 with enhanced agonist activity |
EA201891983A8 (ru) | 2016-03-04 | 2020-05-28 | Бристол-Майерс Сквибб Компани | Комбинированная терапия антителами к cd73 |
EP3448891A1 (en) | 2016-04-28 | 2019-03-06 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
KR102417687B1 (ko) | 2016-05-09 | 2022-07-07 | 브리스톨-마이어스 스큅 컴퍼니 | Tl1a 항체 및 그의 용도 |
TWI822521B (zh) | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
WO2017201476A1 (en) * | 2016-05-20 | 2017-11-23 | Regeneron Pharmaceuticals, Inc. | Methods for breaking immunological tolerance using multiple guide rnas |
PL3462853T3 (pl) | 2016-06-03 | 2023-06-26 | Regeneron Pharmaceuticals, Inc. | Gryzonie wykazujące ekspresję egzogennej terminalnej transferazy deoksynukleotydowej |
WO2017218515A1 (en) | 2016-06-14 | 2017-12-21 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibodies and uses thereof |
CN109641049B (zh) * | 2016-06-21 | 2023-07-07 | 特尼奥生物股份有限公司 | Cd3结合抗体 |
JP7027401B2 (ja) | 2016-07-14 | 2022-03-01 | ブリストル-マイヤーズ スクイブ カンパニー | Tim3に対する抗体およびその使用 |
BR112019003601A2 (pt) | 2016-08-26 | 2019-05-21 | Sanofi | anticorpos multiespecíficos que facilitam pareamento |
US10981976B2 (en) | 2016-08-31 | 2021-04-20 | University Of Rochester | Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof |
AU2017327723B2 (en) | 2016-09-14 | 2022-11-17 | Teneobio, Inc. | CD3 binding antibodies |
CN110214026B (zh) | 2016-09-23 | 2023-12-05 | 瑞泽恩制药公司 | 双特异性抗muc16-cd3抗体和抗muc16药物结合物 |
WO2018058001A1 (en) | 2016-09-23 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof |
CN109996560A (zh) | 2016-10-13 | 2019-07-09 | 麻省理工学院 | 结合寨卡病毒包膜蛋白的抗体及其用途 |
EP3580238A1 (en) | 2017-02-10 | 2019-12-18 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
BR112019016374A2 (pt) | 2017-02-17 | 2020-04-07 | Bristol-Myers Squibb Company | anticorpos para alfa-sinucleína e usos dos mesmos |
CN110382529B (zh) | 2017-03-02 | 2024-03-08 | 诺华股份有限公司 | 工程化的异源二聚体蛋白质 |
WO2018182422A1 (en) | 2017-03-31 | 2018-10-04 | Merus N.V. | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene |
US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
JP7240335B2 (ja) | 2017-06-20 | 2023-03-15 | テネオワン, インコーポレイテッド | 抗bcma重鎖のみ抗体 |
TW201919582A (zh) | 2017-07-24 | 2019-06-01 | 美商再生元醫藥公司 | 穩定化之抗體組合物及其製法 |
SG11202001050PA (en) | 2017-08-09 | 2020-03-30 | Merus Nv | Antibodies that bind egfr and cmet |
AU2018341587A1 (en) | 2017-09-29 | 2020-04-23 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof |
EP3724226A1 (en) | 2017-12-13 | 2020-10-21 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
CR20200322A (es) | 2017-12-22 | 2021-01-12 | Teneobio Inc | Anticuerpos de cadena pesada que se unen a cd22 |
US20220089720A1 (en) | 2018-01-12 | 2022-03-24 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
EP3743442A1 (en) | 2018-01-26 | 2020-12-02 | Regeneron Pharmaceuticals, Inc. | Human antibodies to influenza hemagglutinin |
CN111886256A (zh) | 2018-03-23 | 2020-11-03 | 百时美施贵宝公司 | 抗mica和/或micb抗体及其用途 |
RU2020131383A (ru) | 2018-03-24 | 2022-04-26 | Ридженерон Фармасьютикалз, Инк. | Генетически модифицированные животные, отличные от человека, для выработки терапевтических антител против комплексов пептид-mhc, способы их получения и варианты применения |
AU2019262953A1 (en) | 2018-04-30 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof |
SG11202011232VA (en) | 2018-05-17 | 2020-12-30 | Regeneron Pharma | Anti-cd63 antibodies, conjugates, and uses thereof |
PL3629720T3 (pl) | 2018-06-14 | 2022-05-02 | Regeneron Pharmaceuticals, Inc. | Zwierzęta inne niż człowiek zdolne do rearanżacji dh-dh w sekwencjach kodujących łańcucha ciężkiego immunoglobuliny |
CN112351820A (zh) | 2018-06-21 | 2021-02-09 | 瑞泽恩制药公司 | 双特异性抗psma x抗cd28抗体及其用途 |
BR112021000186A2 (pt) | 2018-07-19 | 2021-08-10 | Regeneron Pharmaceuticals, Inc. | anticorpos anti-bcma x anti-cd3 biespecíficos e usos dos mesmos |
KR20210049863A (ko) | 2018-08-23 | 2021-05-06 | 리제너론 파아마슈티컬스, 인크. | 항-Fc 엡실론-R1 알파 (FCERIA) 항체, FCERIA 및 CD3에 결합하는 이중특이적 항원-결합 분자 및 이들의 용도 |
CN112771077A (zh) | 2018-08-31 | 2021-05-07 | 瑞泽恩制药公司 | 针对cd3/c20双特异性抗体的减轻细胞因子释放综合征的给药策略 |
SG11202101037QA (en) | 2018-10-23 | 2021-02-25 | Regeneron Pharma | Anti-npr1 antibodies and uses thereof |
EP3880708A1 (en) | 2018-11-16 | 2021-09-22 | Bristol-Myers Squibb Company | Anti-nkg2a antibodies and uses thereof |
JP7463366B2 (ja) | 2018-11-20 | 2024-04-08 | タケダ ワクチン,インコーポレイテッド | 新規の抗ジカウイルス抗体及びその使用 |
MA54540A (fr) | 2018-12-19 | 2021-10-27 | Regeneron Pharma | Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations |
EP3898695A1 (en) | 2018-12-19 | 2021-10-27 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof |
US20220090125A1 (en) | 2018-12-21 | 2022-03-24 | Compass Therapeutics Llc | Transgenic mouse expressing common human light chain |
CA3127236A1 (en) | 2019-01-22 | 2020-07-30 | Bristol-Myers Squibb Company | Antibodies against il-7r alpha subunit and uses thereof |
AU2020226445A1 (en) | 2019-02-18 | 2021-07-08 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with humanized immunoglobulin locus |
EP3927153A1 (en) | 2019-02-22 | 2021-12-29 | Regeneron Pharmaceuticals, Inc. | Rodents having genetically modified sodium channels and methods of use thereof |
KR20210142659A (ko) | 2019-03-22 | 2021-11-25 | 리제너론 파아마슈티컬스, 인크. | Egfr×cd28 다중특이성 항체 |
AU2020289554A1 (en) | 2019-06-05 | 2021-11-18 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof |
MA56205A (fr) | 2019-06-11 | 2022-04-20 | Regeneron Pharma | Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation |
JOP20210323A1 (ar) | 2019-06-14 | 2023-01-30 | Teneobio Inc | ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3 |
US20200399371A1 (en) | 2019-06-21 | 2020-12-24 | Regeneron Pharmaceuticals, Inc. | Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation |
KR20220024594A (ko) | 2019-06-21 | 2022-03-03 | 리제너론 파마슈티칼스 인코포레이티드 | Psma 및 cd3에 결합하는 이중 특이적 항원 결합 분자와 4-1bb 공동 자극의 병용 |
JP2022543669A (ja) | 2019-08-08 | 2022-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 新規抗原結合分子フォーマット |
TW202120553A (zh) | 2019-08-15 | 2021-06-01 | 美商再生元醫藥公司 | 用於細胞靶向之多特異性抗原結合分子及其用途 |
GB201912008D0 (en) | 2019-08-21 | 2019-10-02 | Cambridge Entpr Ltd | Antibody |
EP4051707A1 (en) | 2019-10-28 | 2022-09-07 | Regeneron Pharmaceuticals, Inc. | Anti-hemagglutinin antibodies and methods of use thereof |
CN114901678A (zh) | 2019-12-02 | 2022-08-12 | 瑞泽恩制药公司 | 肽-mhc ii蛋白构建体及其用途 |
AU2020398167A1 (en) | 2019-12-06 | 2022-07-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
AU2021218675A1 (en) | 2020-02-11 | 2022-08-18 | Regeneron Pharmaceuticals, Inc. | Anti-ACVR1 antibodies and uses thereof |
EP4186564A1 (en) | 2020-04-29 | 2023-05-31 | Teneoone, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
EP4149976A1 (en) | 2020-05-12 | 2023-03-22 | Regeneron Pharmaceuticals, Inc. | Anti-glp1r antagonist antibodies and methods of use thereof |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
CA3182925A1 (en) * | 2020-06-02 | 2021-12-09 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with common light chain immunoglobulin locus |
EP4200332A1 (en) * | 2020-08-19 | 2023-06-28 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
WO2022056276A1 (en) | 2020-09-11 | 2022-03-17 | Regeneron Pharmaceuticals, Inc. | Identification and production of antigen-specific antibodies |
EP4214234A1 (en) | 2020-09-18 | 2023-07-26 | Regeneron Pharmaceuticals, Inc. | Antigen-binding molecules that bind cd38 and/or cd28, and uses thereof |
IL301702A (en) | 2020-10-22 | 2023-05-01 | Regeneron Pharma | Anti-FGFR2 antibodies and methods of using them |
CN114524878A (zh) | 2020-11-23 | 2022-05-24 | 康诺亚生物医药科技(成都)有限公司 | 一种双特异性抗体及其用途 |
KR20230147048A (ko) | 2020-12-16 | 2023-10-20 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 Fc 알파 수용체를 발현하는 마우스 |
TW202242114A (zh) | 2020-12-23 | 2022-11-01 | 美商再生元醫藥公司 | 用於獲得結合至跨膜蛋白之抗體以及抗體生成細胞的方法 |
US20220195014A1 (en) | 2020-12-23 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
KR20230157315A (ko) | 2021-01-28 | 2023-11-16 | 리제너론 파마슈티칼스 인코포레이티드 | 사이토카인 방출 증후군을 치료하기 위한 조성물 및 방법 |
KR20230156079A (ko) | 2021-03-09 | 2023-11-13 | 젠코어 인코포레이티드 | Cd3과 cldn6에 결합하는 이종이량체 항체 |
JP2024509274A (ja) | 2021-03-10 | 2024-02-29 | ゼンコア インコーポレイテッド | Cd3及びgpc3に結合するヘテロ二量体抗体 |
US20230250170A1 (en) | 2021-12-06 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Antagonist anti-npr1 antibodies and methods of use thereof |
TW202400228A (zh) | 2022-02-25 | 2024-01-01 | 美商再生元醫藥公司 | 減輕細胞激素釋放症候群的給藥方案 |
WO2023196903A1 (en) | 2022-04-06 | 2023-10-12 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof |
WO2023201226A1 (en) | 2022-04-11 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
US20230416396A1 (en) | 2022-05-18 | 2023-12-28 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof |
WO2024015816A1 (en) | 2022-07-12 | 2024-01-18 | Regeneron Pharmaceuticals, Inc. | Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof |
Family Cites Families (141)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1341351C (en) | 1988-09-06 | 2002-03-26 | Marc D. Better | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
DK0502976T3 (da) | 1989-12-01 | 1996-11-11 | Pharming Bv | Produktion af rekombinante polypeptider ved bovine arter og transgene fremgangsmåder |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) * | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
US7041871B1 (en) * | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US7084260B1 (en) | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
US6255458B1 (en) * | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5667988A (en) * | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
US7067284B1 (en) * | 1992-01-27 | 2006-06-27 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
EP0652950B1 (en) | 1992-07-24 | 2007-12-19 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
DE69308573T2 (de) | 1992-08-17 | 1997-08-07 | Genentech Inc | Bispezifische immunoadhesine |
US5693506A (en) | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
EP1149898A2 (en) | 1993-12-23 | 2001-10-31 | Infigen, Inc. | Embryonic stem cells as nuclear donors and nuclear transfer techniques to produce chimeric and transgenic animals |
ES2247204T3 (es) | 1994-01-31 | 2006-03-01 | Trustees Of Boston University | Bancos de anticuerpos policlonales. |
US7119248B1 (en) | 1994-04-12 | 2006-10-10 | Miltenyi Biotec Gmbh | Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof |
US6080560A (en) | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
ATE218143T1 (de) | 1996-09-03 | 2002-06-15 | Gsf Forschungszentrum Umwelt | Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität |
KR100643058B1 (ko) | 1996-12-03 | 2006-11-13 | 아브게닉스, 인크. | 복수의 Vн 및 Vк 영역을 함유하는 인간 면역글로불린 유전자좌를 갖는 트랜스제닉 포유동물 및 이로부터 생성된 항체 |
BR9808192A (pt) | 1997-03-06 | 2000-10-24 | Infigen Inc | Processo de clonagem de animais |
DK0970126T3 (da) | 1997-04-14 | 2001-08-13 | Micromet Ag | Hidtil ukendt fremgangsmåde til fremstillingen af anti-humant antigen-receptorer og anvendelser deraf |
DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
US20020062010A1 (en) * | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US6774279B2 (en) | 1997-05-30 | 2004-08-10 | Carnegie Institution Of Washington | Use of FLP recombinase in mice |
CN1277632A (zh) | 1997-10-03 | 2000-12-20 | 中外制药株式会社 | 天然人源化抗体 |
ATE302271T1 (de) | 1997-11-18 | 2005-09-15 | Pioneer Hi Bred Int | Zusammensetzungen und verfahren für die genetische modifizierung von pflanzen |
GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
ATE536417T1 (de) | 1999-04-15 | 2011-12-15 | Crucell Holland Bv | Herstellung von rekombinanten proteinen in einer menschlichen zelle mit mindestens einem e1 adenovirus protein |
CA2401965A1 (en) | 2000-02-29 | 2001-09-07 | Auburn University | Production of antibodies in transgenic plastids |
CN101498731A (zh) | 2000-05-18 | 2009-08-05 | 日本烟草产业株式会社 | 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途 |
US6936747B2 (en) | 2000-07-21 | 2005-08-30 | The United States Of America As Represented By The Secretary Of Agriculture | Methods for the replacement, translocation and stacking of DNA in eukaryotic genomes |
EP1311530A4 (en) | 2000-08-03 | 2004-10-06 | Wim-Van Schooten | PRODUCTION OF HUMANIZED ANTIBODIES IN TRANSGENIC ANIMALS |
EP1184458A1 (en) | 2000-08-28 | 2002-03-06 | U-BISys B.V. | Differentially expressed CD46 epitopes, proteinaceous molecules capable of binding thereto, and uses thereof |
US20020119148A1 (en) | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
US7105348B2 (en) * | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
ATE464322T1 (de) | 2001-01-05 | 2010-04-15 | Pfizer | Antikörper gegen den rezeptor für den insulinähnlichen wachstumsfaktor i |
US6961875B2 (en) | 2001-03-22 | 2005-11-01 | International Business Machines Corporation | Method and apparatus for capturing event traces for debug and analysis |
GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
EP1399484B1 (en) | 2001-06-28 | 2010-08-11 | Domantis Limited | Dual-specific ligand and its use |
EP1539233B1 (en) | 2001-07-12 | 2011-04-27 | FOOTE, Jefferson | Super humanized antibodies |
US20030138440A1 (en) | 2001-07-19 | 2003-07-24 | Fang Fang | Multimeric proteins and methods of making and using same |
PT1652920E (pt) | 2001-10-01 | 2010-11-08 | Deutsches Krebsforsch | Processo para a produção de bibliotecas de proteínas e para a selecção de proteínas a partir da mesma |
WO2003031656A1 (en) * | 2001-10-05 | 2003-04-17 | United States Environmental Protection Agency | Genetic testing for male factor infertility |
US20060199204A1 (en) * | 2001-10-05 | 2006-09-07 | U.S. Epa | Genetic testing for male factor infertility |
DK1461442T3 (en) | 2001-11-30 | 2017-12-04 | Amgen Fremont Inc | Transgenic animals with human Ig lambda light chain genes |
GB0130267D0 (en) | 2001-12-19 | 2002-02-06 | Neutec Pharma Plc | Focussed antibody technology |
AU2003214842A1 (en) | 2002-01-17 | 2003-09-02 | Albert Einstein College Of Medicine Of Yeshiva University | Mutations caused by activation-induced cytidine deaminase |
IL162844A0 (en) | 2002-01-18 | 2005-11-20 | Inovio As | Use of an expression vector for preparing pharmaceutical compositions |
US7732149B2 (en) | 2002-04-26 | 2010-06-08 | Chugai Seiyaku Kabushiki Kaisha | Methods of screening agonistic antibodies |
KR101143035B1 (ko) | 2002-06-14 | 2012-05-08 | 이뮤노메딕스, 인코오포레이티드 | 단클론 항체 hPAM4 |
CN101962408A (zh) | 2002-07-12 | 2011-02-02 | 杰斐逊·富特 | 超人源化抗体 |
ATE514717T1 (de) * | 2002-07-18 | 2011-07-15 | Merus B V | Rekombinante produktion von antikörpermischungen |
CL2003002461A1 (es) | 2002-11-27 | 2005-01-07 | Dow Chemical Company Agroscien | Inmunoglobulina que comprende al menos un glicano afucosilado, composicion que la contiene, secuencia nucleotidica y vector que la comprende, procedimiento para producir dicha inmunoglobulina en plantas. |
GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
EP1439234A1 (en) | 2003-01-08 | 2004-07-21 | ARTEMIS Pharmaceuticals GmbH | Targeted transgenesis using the rosa26 locus |
ATE431423T1 (de) | 2003-01-21 | 2009-05-15 | Chugai Pharmaceutical Co Ltd | Verfahren zum screening der leichten kette eines antikörpers |
WO2004067753A2 (en) | 2003-01-28 | 2004-08-12 | Cellectis | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof. |
US20070009957A1 (en) | 2003-03-04 | 2007-01-11 | Alexion Pharmaceuticals, Inc. | Vectors used to create hybrid constant regions |
US20100069614A1 (en) * | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
EP2395016A3 (en) | 2003-05-30 | 2012-12-19 | Merus B.V. | Design and use of paired variable regions of specific binding molecules |
MXPA06000562A (es) | 2003-07-15 | 2006-03-30 | Therapeutic Human Polyclonals | Loci de inmunoglobulina humanizada. |
US20050153392A1 (en) | 2003-08-11 | 2005-07-14 | Roland Buelow | Transgenesis with humanized immunoglobulin loci |
WO2005038001A2 (en) | 2003-10-14 | 2005-04-28 | Therapeutic Human Polyclonals, Inc. | Improved transgenesis by sperm-mediated gene transfer |
ATE504599T1 (de) | 2004-01-16 | 2011-04-15 | Regeneron Pharma | Zur aktivierung von rezeptoren fähige fusionspolypeptide |
CN1560081A (zh) | 2004-02-17 | 2005-01-05 | 大连帝恩生物工程有限公司 | 用能产生人IgGl重链-κ轻链小鼠作为制备人源化单克隆抗体和应用 |
US7625549B2 (en) | 2004-03-19 | 2009-12-01 | Amgen Fremont Inc. | Determining the risk of human anti-human antibodies in transgenic mice |
EP1802193B1 (en) | 2004-10-19 | 2014-04-30 | Regeneron Pharmaceuticals, Inc. | Method for generating a mouse homozygous for a genetic modification |
CA2584814A1 (en) | 2004-10-22 | 2006-05-04 | Therapeutic Human Polyclonals, Inc. | Suppression of endogenous immunoglobulin expression in non-human transgenic animals |
CN101132811B (zh) * | 2004-10-22 | 2012-05-30 | 米迪缪尼有限公司 | 抗hmgb1的高亲和力抗体及其用法 |
AU2006242854A1 (en) | 2005-04-29 | 2006-11-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Transgenic animals and methods of making recombinant antibodies |
MX2007014139A (es) | 2005-05-14 | 2008-10-09 | Univ Fudan | Piggybac como una herramienta para manipulacion genetica y analisis en vertebrados. |
FR2888850B1 (fr) | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
EP2314619A1 (en) * | 2005-12-05 | 2011-04-27 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
BRPI0706750A2 (pt) | 2006-01-25 | 2011-04-05 | Univ Erasmus Medical Ct | geração de anticorpos de cadeia pesada em animais transgênicos |
US7462759B2 (en) | 2006-02-03 | 2008-12-09 | Pioneer Hi-Bred International, Inc. | Brittle stalk 2 gene family and related methods and uses |
JP5514539B2 (ja) * | 2006-03-31 | 2014-06-04 | メダレックス・リミテッド・ライアビリティ・カンパニー | ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物 |
CA2652976C (en) * | 2006-06-02 | 2015-08-11 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human il-6 receptor |
US8084024B2 (en) | 2006-08-22 | 2011-12-27 | G2 Inflammation Pty Ltd | Method for producing antibodies |
MY149079A (en) | 2006-10-02 | 2013-07-15 | Regeneron Pharma | High affinity human antibodies to human il-4 receptor |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
US9127064B2 (en) | 2006-12-21 | 2015-09-08 | Novo Nordisk A/S | Antibodies against human NKG2D and uses thereof |
GB0700194D0 (en) | 2007-01-05 | 2007-02-14 | Univ Edinburgh | Humanisation of animals |
WO2008112922A2 (en) | 2007-03-13 | 2008-09-18 | National Jewish Medical And Research Center | Methods for generation of antibodies |
HUE037302T2 (hu) | 2007-06-01 | 2018-08-28 | Open Monoclonal Tech Inc | Készítmények és eljárások endogén immunglobulin gének gátlására és transzgenikus humán idiotipikus antianyagok elõállítása |
WO2009013620A2 (en) | 2007-06-11 | 2009-01-29 | Erasmus University Medical Center Rotterdam | Homologous recombination |
ITMI20071522A1 (it) * | 2007-07-27 | 2009-01-28 | Areta Internat S R L | Vaccino idiotipico |
JP5588866B2 (ja) | 2007-08-10 | 2014-09-10 | メダレックス エル.エル.シー. | Hco32およびhco27、ならびに関連実施例 |
US8933197B2 (en) | 2007-08-15 | 2015-01-13 | Amunix Operating Inc. | Compositions comprising modified biologically active polypeptides |
DK3124497T3 (da) | 2007-09-14 | 2020-05-11 | Adimab Llc | Rationelt designede syntetiske antistofbiblioteker og anvendelser deraf |
EP2211903A4 (en) | 2007-10-17 | 2011-07-06 | Nuvelo Inc | CLL-1 ANTIBODY |
DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
US8012714B2 (en) | 2008-04-14 | 2011-09-06 | Innovative Targeting Solutions, Inc. | Sequence diversity generation in immunoglobulins |
ES2436044T3 (es) | 2008-05-23 | 2013-12-26 | Ablexis, Llc | Procedimiento de generación de anticuerpos de dominio VL individual en animales transgénicos |
RU2559524C2 (ru) | 2008-06-27 | 2015-08-10 | Мерюс Б.В. | Продуцирующие антитела млекопитающие, не являющиеся человеком |
EP3889265A1 (en) | 2008-09-30 | 2021-10-06 | Ablexis, LLC | Transgenic mice for the production of chimeric antibodies |
WO2010054007A1 (en) | 2008-11-07 | 2010-05-14 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
JP5827127B2 (ja) | 2008-12-18 | 2015-12-02 | エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム | ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用 |
EP2401298A1 (en) | 2009-02-24 | 2012-01-04 | Glaxo Group Limited | Antigen-binding constructs |
CN102427978B (zh) | 2009-05-07 | 2016-01-20 | 沃尔沃建筑设备公司 | 工程机械和用于操作工程机械的方法 |
JP5804521B2 (ja) | 2009-05-29 | 2015-11-04 | モルフォシス・アー・ゲー | コレクション及びその使用方法 |
MY164121A (en) | 2009-06-26 | 2017-11-30 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
PT2517556E (pt) | 2009-07-08 | 2016-01-20 | Kymab Ltd | Modelos animais e moléculas terapêuticas |
US20120204278A1 (en) * | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
EP2502993B1 (en) | 2009-11-17 | 2017-07-26 | Sanford Applied Biosciences L.L.C. | Human artificial chromosome vector |
CA2782936C (en) | 2009-12-10 | 2019-06-18 | Regeneron Pharmaceuticals, Inc. | Mice that make heavy chain antibodies |
US20130045492A1 (en) * | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
LT3095871T (lt) | 2010-02-08 | 2019-05-27 | Regeneron Pharmaceuticals, Inc. | Bendros lengvosios grandinės pelė |
US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
CN103228130B (zh) | 2010-06-17 | 2016-03-16 | 科马布有限公司 | 动物模型及治疗分子 |
BR112012033248A2 (pt) | 2010-06-22 | 2017-11-28 | Regeneron Pharma | camundongos expressando uma cadeia leve com variável de lâmbda humana e regiões constantes de camundongo |
SG10201912639SA (en) | 2010-08-02 | 2020-02-27 | Regeneron Pharma | Mice that make binding proteins comprising vl domains |
SG10201913160QA (en) | 2011-02-25 | 2020-03-30 | Regeneron Pharma | Adam6 mice |
US10130081B2 (en) | 2011-08-05 | 2018-11-20 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
IN2014CN03572A (sr) | 2011-10-17 | 2015-10-09 | Regeneron Pharma | |
GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
EP3165086A1 (en) | 2012-03-06 | 2017-05-10 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
KR20150023535A (ko) | 2012-06-05 | 2015-03-05 | 리제너론 파마슈티칼스 인코포레이티드 | 공통 경쇄를 사용하여 완전한 인간 이중 특이적 항체를 만드는 방법 |
SG11201506294TA (en) | 2013-03-13 | 2015-09-29 | Regeneron Pharma | Common light chain mouse |
FI3501272T3 (fi) | 2013-03-13 | 2023-04-06 | Regeneron Pharma | Rajallista immunoglobuliinin kevytketjuvalikoimaa ilmentäviä hiiriä |
-
2011
- 2011-02-08 LT LTEP16178223.0T patent/LT3095871T/lt unknown
- 2011-02-08 WO PCT/US2011/023971 patent/WO2011097603A1/en active Application Filing
- 2011-02-08 CN CN201510354745.2A patent/CN105010238B/zh active Active
- 2011-02-08 PL PL11703799T patent/PL2501817T5/pl unknown
- 2011-02-08 ES ES12173456T patent/ES2603559T5/es active Active
- 2011-02-08 BR BR122014002928A patent/BR122014002928A2/pt not_active Application Discontinuation
- 2011-02-08 US US13/022,759 patent/US10143186B2/en active Active
- 2011-02-08 NZ NZ601679A patent/NZ601679A/en unknown
- 2011-02-08 RU RU2015147726A patent/RU2724663C2/ru active
- 2011-02-08 SG SG10201913463QA patent/SG10201913463QA/en unknown
- 2011-02-08 SI SI201131725T patent/SI3095871T1/sl unknown
- 2011-02-08 DK DK12173456.0T patent/DK2505654T4/da active
- 2011-02-08 DK DK16178223.0T patent/DK3095871T3/da active
- 2011-02-08 MY MYPI2012003497A patent/MY166529A/en unknown
- 2011-02-08 MX MX2012009168A patent/MX2012009168A/es active IP Right Grant
- 2011-02-08 EP EP11703799.4A patent/EP2501817B2/en active Active
- 2011-02-08 EP EP16178223.0A patent/EP3095871B1/en active Active
- 2011-02-08 NZ NZ719253A patent/NZ719253A/en unknown
- 2011-02-08 MX MX2015007651A patent/MX350983B/es unknown
- 2011-02-08 KR KR1020207014664A patent/KR102283195B1/ko active IP Right Grant
- 2011-02-08 PL PL16178223T patent/PL3095871T3/pl unknown
- 2011-02-08 TR TR2019/06650T patent/TR201906650T4/tr unknown
- 2011-02-08 EP EP12173456.0A patent/EP2505654B2/en active Active
- 2011-02-08 SI SI201130642T patent/SI2501817T2/sl unknown
- 2011-02-08 SG SG10201500821UA patent/SG10201500821UA/en unknown
- 2011-02-08 ME MEP-2015-197A patent/ME02288B/me unknown
- 2011-02-08 KR KR1020197018579A patent/KR102116296B1/ko active IP Right Grant
- 2011-02-08 CN CN201180013714.0A patent/CN102791866B/zh active Active
- 2011-02-08 RS RS20190849A patent/RS59001B1/sr unknown
- 2011-02-08 PT PT117037994T patent/PT2501817E/pt unknown
- 2011-02-08 KR KR1020217023446A patent/KR102432611B1/ko active IP Right Grant
- 2011-02-08 PT PT121734560T patent/PT2505654T/pt unknown
- 2011-02-08 ME MEP-2016-271A patent/ME02646B/me unknown
- 2011-02-08 KR KR1020187003853A patent/KR101995735B1/ko active IP Right Grant
- 2011-02-08 AU AU2011213585A patent/AU2011213585B2/en active Active
- 2011-02-08 NZ NZ631363A patent/NZ631363A/en unknown
- 2011-02-08 DK DK11703799.4T patent/DK2501817T4/da active
- 2011-02-08 EP EP19157278.3A patent/EP3540066A1/en active Pending
- 2011-02-08 PT PT16178223T patent/PT3095871T/pt unknown
- 2011-02-08 KR KR1020127021534A patent/KR101829691B1/ko active IP Right Grant
- 2011-02-08 ES ES16178223T patent/ES2728942T3/es active Active
- 2011-02-08 HU HUE12173456A patent/HUE029785T2/en unknown
- 2011-02-08 LT LTEP12173456.0T patent/LT2505654T/lt unknown
- 2011-02-08 SI SI201131024T patent/SI2505654T2/sl unknown
- 2011-02-08 HU HUE16178223A patent/HUE045591T2/hu unknown
- 2011-02-08 RS RS20150772A patent/RS54367B2/sr unknown
- 2011-02-08 ES ES11703799T patent/ES2547142T5/es active Active
- 2011-02-08 PL PL12173456T patent/PL2505654T5/pl unknown
- 2011-02-08 RU RU2012138431/10A patent/RU2571205C2/ru active
- 2011-02-08 JP JP2012552144A patent/JP5955781B2/ja active Active
- 2011-02-08 BR BR112012019887-4A patent/BR112012019887B1/pt active IP Right Grant
- 2011-02-08 RS RS20161014A patent/RS55315B2/sr unknown
- 2011-02-08 HU HUE11703799A patent/HUE026229T2/en unknown
- 2011-02-08 NZ NZ619512A patent/NZ619512A/en unknown
- 2011-02-08 CA CA2789154A patent/CA2789154A1/en active Pending
- 2011-02-08 SG SG2012057485A patent/SG183149A1/en unknown
-
2012
- 2012-03-06 US US13/412,936 patent/US20120192300A1/en not_active Abandoned
- 2012-08-02 IL IL221265A patent/IL221265B/en active IP Right Grant
- 2012-08-07 ZA ZA2012/05944A patent/ZA201205944B/en unknown
- 2012-08-08 MX MX2021000286A patent/MX2021000286A/es unknown
- 2012-10-17 HK HK17104973.4A patent/HK1231505A1/zh unknown
-
2013
- 2013-02-06 HK HK13101647.0A patent/HK1174358A1/zh unknown
- 2013-03-05 SG SG10201610294RA patent/SG10201610294RA/en unknown
- 2013-07-23 US US13/948,818 patent/US20130302836A1/en not_active Abandoned
-
2015
- 2015-07-02 JP JP2015133610A patent/JP6215264B2/ja active Active
- 2015-11-05 HR HRP20151188TT patent/HRP20151188T4/hr unknown
- 2015-11-19 SM SM201500283T patent/SMT201500283B/it unknown
-
2016
- 2016-11-17 CY CY20161101191T patent/CY1118241T1/el unknown
- 2016-11-22 HR HRP20161551TT patent/HRP20161551T4/hr unknown
- 2016-11-24 SM SM201600432T patent/SMT201600432B/it unknown
-
2017
- 2017-05-24 JP JP2017102567A patent/JP6470789B2/ja active Active
-
2018
- 2018-05-01 JP JP2018088350A patent/JP2018138047A/ja active Pending
- 2018-10-19 US US16/165,987 patent/US10986820B2/en active Active
-
2019
- 2019-01-18 JP JP2019006594A patent/JP6666483B2/ja active Active
- 2019-06-16 IL IL267362A patent/IL267362B/en unknown
- 2019-07-01 HR HRP20191191TT patent/HRP20191191T1/hr unknown
- 2019-07-05 CY CY20191100710T patent/CY1121794T1/el unknown
-
2020
- 2020-02-20 JP JP2020027029A patent/JP6960005B2/ja active Active
-
2021
- 2021-03-23 US US17/209,964 patent/US20210204531A1/en active Pending
- 2021-10-08 JP JP2021166030A patent/JP7233504B2/ja active Active
-
2022
- 2022-01-24 IL IL290085A patent/IL290085A/en unknown
-
2023
- 2023-02-21 JP JP2023025117A patent/JP2023062142A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL290085A (en) | A common light chain mouse | |
AU2016202488A1 (en) | Common light chain mouse | |
HK1205873A1 (en) | Common light chain mouse | |
ZA201404600B (en) | Hybrid light chain mice | |
EP2609366A4 (en) | LIGHT FUNCTION | |
AU2014202445B2 (en) | Common light chain mouse | |
GB2478365B (en) | Light | |
TWM389815U (en) | LED light | |
TWM387201U (en) | Light | |
AU330289S (en) | Light | |
AU329890S (en) | Light | |
GB201014527D0 (en) | Chain | |
AU334605S (en) | Luminaire | |
AU334604S (en) | Luminaire | |
GB201017396D0 (en) | Luminaire |